secwatch.observer — SEC 8-K summary
======================================

Issuer:     Altimmune, Inc. (ALT)
CIK:        0001326190
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0001326190-22-000010
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Altimmune Q3 net loss $23.5M, cash $201.9M; pemvidutide NAFLD data mid-Dec, obesity interim Q1 2023
--------------------------------------------------------------------------------

- Net loss of $23.5M ($0.48 per share) vs $33.5M loss YoY; revenue minimal at ~$0.
- Cash, equivalents & short-term investments totaled $201.9M at September 30, 2022.
- Topline 24-week data from Phase 1b NAFLD trial expected mid-December 2022.
- Interim 24-week readout from Phase 2 MOMENTUM obesity trial (~160 subjects) expected Q1 2023.
- Enrollment complete in Phase 1b type 2 diabetes trial; data readout expected Q1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326190/000132619022000010/0001326190-22-000010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326190/000132619022000010/alt-20221110x8k.htm
  HTML page:      https://secwatch.observer/filing/0001326190-22-000010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer